UCSF Navigation Bar

UCSF Departments of Pathology & Laboratory Medicine Home Page

Lab Manual for UCSF Clinical Laboratories

Lab Manual for SFGH

Internal Resources

Additional Details

Click on TestEntryNumber to go to the laboratory manual entry for that test

Item Value
ClinicalQuestion Does my patient have antiphospholipid syndrome (APLS)?
TestEntryNumber 168
TestCode ACLG
TestName Anti-Cardiolipin Antibody, IgG
Synonyms Anti-phospholipid antibody; anticardiolipin antibody;
IsThisScreeningTest No
PubMedID 18755986, 16420554, 12393574, 22951216
Comment In the context of diagnosing anti-phospholipid syndrome, anti-cardiolipin IgG and IgM should be performed in conjunction with other laboratory tests (all pertinent labs are included in the antiphopholipid antibody panel) in patients who meet clinical criteria as defined in the revised Sapporo criteria (J Thromb Haemost. 2006;4(2):295). The laboratory evaluation should take place at least 12 weeks after a qualifying clinical event and be repeated at least 12 weeks after the first round of tests. We do not recommend testing for anti-phospholipid syndrome at the time of an acute event. The presence of clinical criteria and at least one positive laboratory criteria (with repeat positivity at least 12 weeks apart) establishes a diagnosis of antiphospholipid syndrome.

Studies have shown that the association of thrombosis is strenghtened with high titers and IgG subtype of anti-cardiolipin. Persistently elevated titers of anti-cardiolipin may be a risk factor for recurrence in patient's with anti-phospholipid syndrome.

Transient elevation in both anti-cardiolipin IgG and IgM titers occur, frequently in infections. These false positives are more frequent with anti-cardiolipin than anti-beta-2-glycoprotein.

Studies have shown that IgG or IgM anti-cardiolipin demonstrate weaker association with thrombosis than a positive lupus anticoagulant test.
Sensitivity NA
Specificity NA
UCSF home page UCSF home page About UCSF Search UCSF UCSF Medical Center